Saturday, November 21, 2026
20.3 C
Bengaluru

DeepSeek – A Precursor to Patent Disruption?

The rise of open-source platforms, such as China’s DeepSeek AI, is poised to transform not just the Tech World but all businesses including pharma. With the power of collaboration and open-source artificial intelligence (AI), initiatives like DeepSeek AI can drive the creation of novel therapeutic targets and molecules. This new model promises to accelerate drug development and address unmet medical needs, challenging the traditional norms of the pharmaceutical industry, especially concerning patents, pricing, and equitable access to medications.

Revolutionizing Drug Discovery

Open-source AI, like DeepSeek, represents a pivotal shift in drug discovery. By using artificial intelligence to analyze vast datasets, researchers can pinpoint promising compounds more quickly and efficiently than traditional methods. This has significant implications: reduced research costs and enhanced collaboration among global scientists, including those in resource-constrained regions. Smaller biotech firms and academic institutions, particularly in developing countries, now have more significant opportunities to contribute to drug development, which could accelerate responses to global health challenges.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

USFDA Crackdown on Indian Pharma: Lessons for Indian Regulator

The US Food and Drug Administration has made unannounced...

The era of regulatory arbitrage in Indian nutraceuticals is officially over.

With the FSSAI suspending licenses across six nutraceutical manufacturers...

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

Indian pharma is investing heavily in digital engagement. But...

Topics

USFDA Crackdown on Indian Pharma: Lessons for Indian Regulator

The US Food and Drug Administration has made unannounced...

The era of regulatory arbitrage in Indian nutraceuticals is officially over.

With the FSSAI suspending licenses across six nutraceutical manufacturers...

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Indian Pharma 2026: The Growth Engine Is Changing

The Indian Pharmaceutical Market isn't just growing. Its centre...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” 💊

India has world-scale formulation capability, yet the chemistry beneath...
spot_img

Related Articles

spot_imgspot_img